The U.S. Food and Drug Administration announced today that information regarding cardiovascular risks has been added to the labeling of the diabetes drug Avandia (rosiglitazone). The changes apply both to the patient Medication Guide and physician labeling.
In September of 2010 the FDA announced that it would restrict the use of the drug to those patients with Type 2 diabetes who were unable to control their disease with other drugs. The move came in response to data showing the drug posed an increased risk of cardiovascular events, including heart attack, in patients taking Avandia.
Thousands of lawsuits relating to Avandia have been filed in recent years. For more information on these and other defective drug lawsuits relating to drugs such as Actos, Levaquin and Cipro, visit Your Legal Guide’s pages focusing on these drugs. Your Legal Guide also contains information on wrongful death lawsuits, including those involving defective drug deaths.